The field of cancer treatment saw a variety of advancements in 2025, from new dedicated centers to approved treatments to ...

USF medical engineering professors Dr. Richard Heller and Dr. Mark Jaroszeski have spent more than three decades developing a ...

Researchers at the Johns Hopkins Kimmel Cancer Center's Ludwig Center developed a new treatment that selectively targets ...

While the current approval focuses on the second-line setting, research is already moving into earlier stages of the ...

No increased risk for cancer was found among patients with RA receiving biologic or targeted synthetic DMARDs vs TNF inhibitors.

An expert discusses how long-term safety considerations are evaluated through clinical trial data and postmarketing surveillance, emphasizing the importance of reporting unexpected adverse events to ...

Leading cancer researchers from UC San Francisco presented talks about advances in targeted therapies, cancer genomics, using AI to personalize cancer treatment, improving diagnosis of hard-to-treat ...

Cancer diagnosis used to be a simple, binary call: either someone had the disease or they didn’t. And patients with the same broad class of cancer tend to receive the same class of therapy. It was a ...

Researchers at the Johns Hopkins Kimmel Cancer Center’s Ludwig Center developed a new treatment that selectively targets ...